Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Status: Enrolling
Updated:  1/29/2018
Breast Health Center, University of California Irvine Medical Center
mi
from
Orange, CA
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Computed Radiography (CR) Data Collection for Mammography Computer Aided Detection (CAD)
Status: Enrolling
Updated: 1/29/2018
Breast Health Center, University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  1/29/2018
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 in Patients With Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 1/29/2018
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated:  1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Phase I Study of High Dose Gefitinib (Iressa) for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations
Status: Enrolling
Updated: 1/29/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Computerized Assessment for Patients With Cancer
Computerized Assessment for Patients With Cancer-ESRA-C II
Status: Enrolling
Updated:  1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Computerized Assessment for Patients With Cancer
Computerized Assessment for Patients With Cancer-ESRA-C II
Status: Enrolling
Updated: 1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Computerized Assessment for Patients With Cancer
Computerized Assessment for Patients With Cancer-ESRA-C II
Status: Enrolling
Updated:  1/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
Computerized Assessment for Patients With Cancer
Computerized Assessment for Patients With Cancer-ESRA-C II
Status: Enrolling
Updated: 1/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
Imaging Vascular Properties of Pediatric Brain Tumors Using DSC-MRI With Ferumoxytol (Code 7228) and DCE-MRI With Gadolinium in a Single Imaging Session: An NCI Sponsored Exploratory Trial
Status: Enrolling
Updated:  1/30/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors
Imaging Vascular Properties of Pediatric Brain Tumors Using DSC-MRI With Ferumoxytol (Code 7228) and DCE-MRI With Gadolinium in a Single Imaging Session: An NCI Sponsored Exploratory Trial
Status: Enrolling
Updated: 1/30/2018
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated:  1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated: 1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated:  1/30/2018
University Health Network
mi
from
Toronto,
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated: 1/30/2018
University Health Network
mi
from
Toronto,
Click here to add this to my saved trials
Improving Sensitivity of Urine Cytology for Bladder Cancer
Non-Invasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer
Status: Enrolling
Updated:  1/30/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Improving Sensitivity of Urine Cytology for Bladder Cancer
Non-Invasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer
Status: Enrolling
Updated: 1/30/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Kaiser Permanente - Souther California
mi
from
Downey, CA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Kaiser Permanente - Souther California
mi
from
Downey, CA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Kaiser Permanente - Southern California
mi
from
Los Angeles, CA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Kaiser Permanente - Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Emory Healthcare
mi
from
Atlanta, GA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Emory Healthcare
mi
from
Atlanta, GA
Click here to add this to my saved trials
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated:  1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
Status: Enrolling
Updated: 1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis
Status: Enrolling
Updated:  1/30/2018
Sibley Memorial Hospital /Johns Hopkins University
mi
from
Washington,
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis
Status: Enrolling
Updated: 1/30/2018
Sibley Memorial Hospital /Johns Hopkins University
mi
from
Washington,
Click here to add this to my saved trials
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/30/2018
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/30/2018
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
Status: Enrolling
Updated:  1/30/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
Status: Enrolling
Updated: 1/30/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/30/2018
University of Colorado Hospital
mi
from
Aurora, CO
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/30/2018
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/30/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/30/2018
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/30/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/30/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/30/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/30/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Status: Enrolling
Updated:  1/30/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Status: Enrolling
Updated: 1/30/2018
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Incidence of SCLN Metastasis in Patients Referred for EBUS-TBNA
Incidence of Supraclavicular Lymph Node Metastasis in Patients Referred for EBUS-TBNA for Presumed Primary Lung Cancer by Interventional Pulmonologists.
Status: Enrolling
Updated:  1/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Incidence of SCLN Metastasis in Patients Referred for EBUS-TBNA
Incidence of Supraclavicular Lymph Node Metastasis in Patients Referred for EBUS-TBNA for Presumed Primary Lung Cancer by Interventional Pulmonologists.
Status: Enrolling
Updated: 1/30/2018
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate
Status: Enrolling
Updated:  1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
Phase II Study of Antineoplaston A10 and AS2-1 Capsules In Patients With Incurable, Stage C or D Adenocarcinoma of the Prostate
Status: Enrolling
Updated: 1/30/2018
Burzynski Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Indiana University
mi
from
Indianapolis, IN
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
John Hopkins University
mi
from
Baltimore, MD
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Cape Cod Healthcare
mi
from
Hyannis, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Cape Cod Healthcare
mi
from
Hyannis, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Lowelll General Hospital
mi
from
Lowell, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Lowelll General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
North Shore Medical Center
mi
from
Peabody, MA
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
North Shore Medical Center
mi
from
Peabody, MA
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Washington University
mi
from
Saint Louis, MO
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
North Shore-LIJ Health System Monter Cancer Center
mi
from
Lake Success, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
North Shore-LIJ Health System Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Weill-Cornell Medical College
mi
from
New York, NY
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Case Western University
mi
from
Cleveland, OH
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
Tennesse Oncology, PLLC, Site # 076
mi
from
Nashville, TN
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
Tennesse Oncology, PLLC, Site # 076
mi
from
Nashville, TN
Click here to add this to my saved trials
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated:  1/30/2018
The University of Vermont Cancer Center
mi
from
Burlington, VT
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Status: Enrolling
Updated: 1/30/2018
The University of Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated:  1/30/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated: 1/30/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Kaiser Permanente - Deer Valley
mi
from
Antioch, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Alta Bates Summit Comprehensive Cancer Center
mi
from
Berkeley, CA
Click here to add this to my saved trials
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated:  1/31/2018
Peninsula Medical Center
mi
from
Burlingame, CA
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
A Phase II Selection Design of Pharmacodynamic Separation of Carboplatin/Paclitaxel/OSI-774 (Erlotinib; NSC-718781) or OSI-774 Alone in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Performance Status 2 (PS-2)
Status: Enrolling
Updated: 1/31/2018
Peninsula Medical Center
mi
from
Burlingame, CA
Click here to add this to my saved trials